Cascadity Audio
← All streams

#glp-1

Everything tagged glp-1, across every stream.

0
MMMarket Movers #earnings#eli-lilly#glp-1#healthcare#obesity-drugs#pharma

Eli Lilly raises its 2026 sales forecast to $91-92 billion as Zepbound and Mounjaro keep growing

CNBC breaks down which drugs beat, the weaker obesity-pill launch, and the CEO's case for a bigger obesity market.

Eli Lilly reported third-quarter revenue of $24.4 billion on October 29, above the $22.61 billion analysts expected, and adjusted earnings of $7.48 a share against $6.26 expected, per LSEG. It raised its 2026 revenue forecast to $91 billion to $92 billion, from $85 billion to $87 billion. Its earnings-per-share outlook moved slightly lower to $35 to $36, because $4.57 a share in deal-related charges more than offset a $4.07 increase in underlying guidance.

Mounjaro revenue rose 65% to $10.72 billion, with sales outside the US up 93%, and Zepbound rose 49% to $5.35 billion. Sales of the new obesity pill Foundayo, launched in April, came in below expectations. CEO Dave Ricks pointed to Medicare's pilot coverage of GLP-1 drugs for weight loss. The stock rose 6% to 8% during the day, and CNBC reports the healthcare sector hit a record high.

Rabbit Holes 1
Generated by AI.
0
RRipples #content-moderation#glp-1#health-misinformation#influencers#peptides#TikTok

TikTok quietly blocks searches for semaglutide, BPC-157 and other popular peptides

The Verge tested the new 'no results' pages and found easy workarounds.

Searches on TikTok for peptides such as semaglutide, BPC-157, TB-500 and retatrutide now return a "no results found" page, The Verge reports. Videos have not been removed, a general search for "peptides" still works, and slight spelling variations get around the block. TikTok's U.S. owner did not immediately respond to The Verge.

Peptides include approved drugs like insulin and GLP-1s, but also unapproved substances that influencers promote, sometimes pointing followers to compounding pharmacies, for uses from weight loss to wound healing with little clinical data, The Verge says. Influencer Jeff Tang flagged the change and blamed Eli Lilly in a video.

Rabbit Holes 1
Generated by AI.
0
LThe Loom #circular-fashion#cobblers#glp-1#repair#tailoring

Weight-loss drugs are keeping US tailors and cobblers busy, as Europe's repair market grows

Belt-shortening by the hundred, and a clear-eyed look at whether clothing repair is a real industry shift.

Americans on GLP-1 drugs such as Ozempic and Mounjaro are altering the clothes they have instead of buying new ones, Reuters reports (via Vijesti and The Independent). Cobblers Direct, which has 25 stores in Texas, says it now shortens up to 500 belts a week; Manhattan's Jim's Cobbler Concierge calls the trend "belt-zempic." Rising out-of-pocket drug costs, a Trimi survey finding about 80% of users wear clothes that no longer fit, and University of Cambridge research showing patients regain an average of 60% of lost weight within a year of stopping make many reluctant to buy a new wardrobe.

In Europe, FashionUnited reports brands from Salomon to Next and Primark launched repair programmes in the first half of 2026. The Fédération de la Mode Circulaire and KPMG value the region's clothing and footwear repair market at about €2.8 billion in 2025, projected to reach €3.7 billion by 2030, though repair is labour-intensive and many low-quality garments aren't worth fixing.

Rabbit Holes 2

Sign in to upvote

Your votes tell us which stories, analysis and rabbit holes are worth it. We'll bring you right back to this spot and count your vote.

Sign in Create an account